JPS632934B2 - - Google Patents
Info
- Publication number
- JPS632934B2 JPS632934B2 JP11953085A JP11953085A JPS632934B2 JP S632934 B2 JPS632934 B2 JP S632934B2 JP 11953085 A JP11953085 A JP 11953085A JP 11953085 A JP11953085 A JP 11953085A JP S632934 B2 JPS632934 B2 JP S632934B2
- Authority
- JP
- Japan
- Prior art keywords
- tocopherol
- bath
- present
- derivative
- nonionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000654 additive Substances 0.000 claims description 23
- 229930003799 tocopherol Natural products 0.000 claims description 16
- 239000011732 tocopherol Substances 0.000 claims description 16
- 230000000996 additive effect Effects 0.000 claims description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 12
- 229960001295 tocopherol Drugs 0.000 claims description 11
- 235000010384 tocopherol Nutrition 0.000 claims description 11
- 229920013820 alkyl cellulose Polymers 0.000 claims description 10
- 239000002736 nonionic surfactant Substances 0.000 claims description 8
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- -1 polyoxyethylene Polymers 0.000 description 7
- 238000003287 bathing Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005187 foaming Methods 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000019149 tocopherols Nutrition 0.000 description 5
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
〔産業上の利用分野〕
本発明は、トコフエロールあるいはその誘導体
を有効成分とする入浴剤に関するものである。
〔従来の技術〕
入浴剤は入浴時浴槽に入れて、入浴剤に含有す
る成分を浴湯中に溶出させ、その成分と入浴時の
身体の状況と相まつて、身体を温めて血液の循環
を良好にし、末梢血管の血流を促進して新陳代謝
を高めたり、又皮膚表面の角質軟化作用により肌
をなめらかにするなどの目的に用いられるもので
ある。
現在、このような入浴剤は、粉、顆粒、錠など
の剤型で、浴湯に透明にとけるものが使用されて
いる。そして、この目的のための薬効成分として
炭酸ナトリウム、塩化ナトリウム、硫酸ナトリウ
ムなどの無機塩類が賦形剤を兼ねて主として使用
されている。
〔発明が解決しようとする問題点〕
上述の無機塩類を成分とする入浴剤は、無機塩
類が水溶性のために、皮脂になじまず皮膚への吸
収が悪く、その薬効が充分ではなかつた。
そこで、本発明者らは、トコフエロールあるい
はその誘導体が油性のため皮脂になじんで皮膚に
吸収され易いことに着目し、トコフエロールある
いはその誘導体を主成分とする入浴剤の製法につ
いて検討した。しかしながら、これらの化学物は
油溶性の性質のため、これを浴湯に溶かすために
加える界面活性剤により浴湯表面に泡立を生じ、
更にトコフエロールあるいはその誘導体特有の湯
垢様浮遊物が生じ、入浴剤として著しくその商品
価値を減ずる難点があつた。
〔問題点を解決するための手段〕
本発明はトコフエロールあるいはその誘導体の
可溶化とそれに伴う泡立ち、ならびに湯垢様浮遊
物の生成のないトコフエロールあるいはその誘導
体を含む入浴剤を得る目的で鋭意研究の結果、非
イオン界面活性剤と非イオン系のアルキルセルロ
ースあるいはその誘導体との組み合わせによつ
て、上述の難点が解消し、トコフエロールあるい
はその誘導体の有する手足のしびれ、手足の冷え
などの末梢血行障害による諸症状などの改善に寄
与する効果を入浴により身体に皮膚吸収により与
える良好な入浴剤を得ることを見出し本発明を完
成した。
本発明はトコフエロールあるいはその誘導体に
非イオン界面活性剤及び非イオン系のアルキルセ
ルロース又はその誘導体を配合してなる浴湯に易
溶性でしかも泡立ち及び湯垢様浮遊物を生じない
入浴剤である。
本発明に使用するトコフエロールは一般にビタ
ミンEと称せられるもので、黄色〜黄褐色の透明
で粘性のある油状物質で、水には殆ど溶けない物
質である。
また、トコフエロール誘導体は酢酸トコフエロ
ール、コハク酸トコフエロール等である。
特に酢酸トコフエロールは無色〜黄色の透明で
粘性のある水に殆ど溶けない物質である。
本発明においては、トコフエロールもトコフエ
ロール誘導体も使用出来るが安定性の点で酢酸ト
コフエロールの方が好ましい。
本発明に使用する非イオン界面活性剤として
は、ポリオキシエチレンアルキルエーテルなどの
エーテル型、ポリオキシエチレンソルビタン脂肪
酸エステルなどのエーテルエステル型及びポリオ
キシエチレン脂肪酸エステルなどのエステル型な
どの公知の非イオン界面活性剤があげられる。本
発明においては、これら非イオン界面活性剤は何
れも使用できるが、HLB15以上好ましくは、17
〜18のものが、入浴剤組成中の添加量も少なくて
すみ好適である。
本発明に使用する非イオン系アルキルセルロー
スあるいはその誘導体としては、メチルセルロー
ス、エチルセルロース等の様にセルロースの水酸
基の一部がアルキルエーテル化されたアルキルセ
ルロース、または、この一部アルキルエーテル化
したアルキルセルロースのエーテル化されていな
い残りの水酸基の一部を他の置換基例えばヒドロ
キシアルキル基で置換したヒドロキシプロピルメ
チルセルロースなどがあげられる。
本発明の入浴剤においては、前記トコフエロー
ル、トコフエロール誘導体に対する非イオン界面
活性剤及び非イオン系アルキルセルロース又はア
ルキルセルロース誘導体の配合割合は製剤化の場
合の他の成分により適宜変更し得るが、大体それ
ぞれ5〜0.2培量(重量)配合することにより本
発明の効果が十分に奏せられる。
本発明の入浴剤は上記トコフエロール、トコフ
エロール誘導体、非イオン界面活性剤、非イオン
系アルキルセルロースあるいはその誘導体の他に
入浴剤として常用の成分、例えば炭酸ナトリウ
ム、塩化ナトリウム、硫酸ナトリウム等の無機塩
類、香料、色素などその使用場面に応じて適宜配
合する。
なお、本発明の入浴剤中のトコフエロール又は
トコフエロール誘導体の量は別に限定されるもの
ではないが大体0.4〜1%程度配合するのが好適
である。
本発明の入浴剤の製剤形としては粉状、錠剤
型、顆粒状等各種の浴湯に投入し易い剤型に通常
の方法によつて製剤化する。
〔実施例〕
次に本発明の入浴剤の実施例をあげる。
例 1
dl―α―酢酸トコフエロール0.4g、ポリオキ
シエチレンノニルフエニルエーテル(HLB17.8)
0.3g及び香料3.0gを混合機で混合し混合液を調
整する。
粉末硫酸ナトリウム95.6g、ヒドロキシプロピ
ルメチルセルロース0.5g及び色素0.2gを混合機
に投入し、混合を続けながら上記混合液をスプレ
ー添加して粉状の製品100gを得る。
例 2
dl―α―トコフエロール0.75g、ポリオキシエ
チレンラウリルエーテル(HLB17.7)0.2g及び
香料3.5gを混合機で混合し混合液を調整する。
硫酸ナトリウム30.0g、乳糖64.35g、色素0.2
g及びメチルセルロース0.5gに少量の水を加え
て混練し、押出し造粒機で径1mmのペレツト状に
造粒し乾燥する。次に、これをポツトミキサーに
投入し、回転しながら上記混合液をスプレー添加
して顆粒状の製品100gを得る。
〔発明の効果〕
本発明の入浴剤は、浴湯に易溶性であり、浴湯
に溶解後も浴湯に泡立ち及び湯垢様の浮遊物が生
じない。
本効果を本発明の入浴剤(実施例1、2の製
品)と実施例1と同様に製造し、実施例1のヒド
ロキシプロピルメチルセルロースの代わりに同量
のカルボキシメチルセルロースを用いた製品(比
較例1)、実施例1のヒドロキシプロピルメチル
セルロースの代わりに同量のポリビニルアルコー
ルを用いた製品(比較品2)及び、実施例1の製
造において、ヒドロキシプロピルメチルセルロー
スを除外して製造した製品(比較品3)を製造
し、それぞれの製品を浴湯180に10gを投入し
た場合の泡立ち並びに湯垢様浮遊物の有無を観察
した結果を下記表に示す。
[Industrial Application Field] The present invention relates to a bath additive containing tocopherol or a derivative thereof as an active ingredient. [Conventional technology] Bath additives are placed in a bathtub when taking a bath, and the ingredients contained in the bath additives are eluted into the bath water.The ingredients, combined with the body's condition at the time of bathing, warm the body and improve blood circulation. It is used for purposes such as promoting blood flow in peripheral blood vessels and increasing metabolism, and smoothing the skin by its keratin softening effect on the skin surface. Currently, such bath additives are in the form of powder, granules, tablets, etc., and are transparent and dissolve in bath water. Inorganic salts such as sodium carbonate, sodium chloride, and sodium sulfate are mainly used as medicinal ingredients for this purpose, and also serve as excipients. [Problems to be Solved by the Invention] Bath additives containing the above-mentioned inorganic salts do not blend well with sebum and are poorly absorbed into the skin because the inorganic salts are water-soluble, resulting in insufficient medicinal efficacy. Therefore, the present inventors focused on the fact that tocopherols or derivatives thereof are oily and therefore easily absorbed into the skin by blending into sebum, and investigated a method for producing bath additives containing tocopherols or derivatives thereof as a main component. However, since these chemicals are oil-soluble, the surfactant added to dissolve them in the bath water causes foaming on the surface of the bath water.
In addition, a scale-like floating substance peculiar to tocopherols or derivatives thereof is generated, which significantly reduces the commercial value of the product as a bath additive. [Means for Solving the Problems] The present invention is the result of intensive research aimed at obtaining a bath additive containing tocopherol or its derivative without solubilization of tocopherol or its derivative, resulting in foaming, and generation of scale-like suspended matter. By combining a nonionic surfactant with a nonionic alkyl cellulose or its derivatives, the above-mentioned difficulties can be overcome, and various problems caused by peripheral blood circulation disorders such as numbness of the hands and feet and coldness caused by tocopherols or their derivatives can be solved. The present invention has been completed by discovering that a good bathing agent can be obtained which provides the effect of contributing to the improvement of symptoms etc. to the body through skin absorption during bathing. The present invention is a bath additive which is easily soluble in bath water and does not produce foaming or scale-like suspended matter, which is prepared by blending tocopherol or its derivative with a nonionic surfactant and a nonionic alkyl cellulose or its derivative. The tocopherol used in the present invention is generally referred to as vitamin E, and is a transparent, viscous, oily substance with a yellow to tan color, and is almost insoluble in water. Further, tocopherol derivatives include tocopherol acetate, tocopherol succinate, and the like. In particular, tocopherol acetate is a colorless to yellow, transparent, viscous substance that is almost insoluble in water. In the present invention, both tocopherol and tocopherol derivatives can be used, but tocopherol acetate is preferred in terms of stability. The nonionic surfactants used in the present invention include known nonionic surfactants such as ether type such as polyoxyethylene alkyl ether, ether ester type such as polyoxyethylene sorbitan fatty acid ester, and ester type such as polyoxyethylene fatty acid ester. Examples include surfactants. In the present invention, any of these nonionic surfactants can be used, but HLB of 15 or more, preferably 17
-18 are preferable because they can be added in small amounts in the bath additive composition. The nonionic alkylcellulose or its derivatives used in the present invention include alkylcellulose in which a portion of the hydroxyl groups of cellulose are alkyl etherified, such as methylcellulose and ethylcellulose, or alkylcellulose in which a portion of the hydroxyl groups of cellulose are alkyl etherified, such as methylcellulose and ethylcellulose. Examples include hydroxypropyl methyl cellulose in which a portion of the remaining hydroxyl groups that have not been etherified are substituted with other substituents, such as hydroxyalkyl groups. In the bath additive of the present invention, the blending ratio of the nonionic surfactant and the nonionic alkylcellulose or alkylcellulose derivative to the tocopherol or tocopherol derivative can be changed as appropriate depending on other ingredients in the formulation, but generally each The effect of the present invention can be sufficiently exhibited by blending the culture medium in an amount (weight) of 5 to 0.2. In addition to the above-mentioned tocopherols, tocopherol derivatives, nonionic surfactants, nonionic alkyl celluloses or derivatives thereof, the bath additives of the present invention include ingredients commonly used in bath additives, such as inorganic salts such as sodium carbonate, sodium chloride, and sodium sulfate. Add fragrances, pigments, etc. as appropriate depending on the usage situation. The amount of tocopherol or tocopherol derivative in the bath additive of the present invention is not particularly limited, but it is preferably about 0.4 to 1%. The bath additives of the present invention can be formulated into various forms such as powder, tablets, and granules that can be easily added to bathwater by conventional methods. [Example] Next, an example of the bath additive of the present invention will be given. Example 1 dl-α-tocopherol acetate 0.4g, polyoxyethylene nonyl phenyl ether (HLB17.8)
Mix 0.3g and 3.0g of fragrance in a mixer to prepare a mixed solution. 95.6 g of powdered sodium sulfate, 0.5 g of hydroxypropyl methylcellulose, and 0.2 g of pigment are placed in a mixer, and while mixing is continued, the above mixture is sprayed to obtain 100 g of a powdered product. Example 2 Mix 0.75 g of dl-α-tocopherol, 0.2 g of polyoxyethylene lauryl ether (HLB17.7), and 3.5 g of fragrance in a mixer to prepare a mixed solution. Sodium sulfate 30.0g, lactose 64.35g, pigment 0.2
g and 0.5 g of methylcellulose are mixed with a small amount of water, granulated into pellets with a diameter of 1 mm using an extrusion granulator, and dried. Next, this is put into a pot mixer, and the above mixed liquid is sprayed while rotating to obtain 100 g of a granular product. [Effects of the Invention] The bath additive of the present invention is easily soluble in bath water, and does not generate foam or scale-like suspended matter in bath water even after being dissolved in bath water. This effect was confirmed by the bath additives of the present invention (products of Examples 1 and 2) and the product manufactured in the same manner as in Example 1 and using the same amount of carboxymethylcellulose instead of the hydroxypropylmethylcellulose of Example 1 (Comparative Example 1). ), a product using the same amount of polyvinyl alcohol instead of hydroxypropyl methylcellulose in Example 1 (Comparative product 2), and a product manufactured in Example 1 by excluding hydroxypropyl methylcellulose (Comparative product 3) The table below shows the results of observing the foaming and presence of scale-like suspended matter when 10 g of each product was added to 180 ml of bath water.
【表】【table】
【表】
以上の如く、本発明の入浴剤は入浴時浴湯に投
入しても入浴時泡立ち、湯垢様浮遊物がなく、不
快感を与えることがない。更に、同入浴剤中の成
分であるトコフエロール又はその誘導体が溶出
し、入浴時の人体の皮膚より吸収され、トコフエ
ロールの有する末梢血管拡張作用、血行促進作用
を体内に及ぼし手足のしびれ、冷えなどの末梢血
行障害による諸症状、熟年期の老化防止に寄与す
るものである。[Table] As described above, even when the bath additive of the present invention is added to bath water during bathing, there is no foaming during bathing, there is no scale-like floating matter, and there is no discomfort. Furthermore, tocopherol or its derivatives, which are ingredients in the bath additive, are eluted and absorbed through the skin of the human body during bathing, exerting the peripheral vasodilation and blood circulation promoting effects of tocopherol in the body, causing numbness in the hands and feet, coldness, etc. It contributes to the prevention of various symptoms caused by peripheral blood circulation disorder and aging in middle age.
Claims (1)
ン界面活性剤及び非イオン系のアルキルセルロー
ス又はその誘導体を配合してなることを特徴とす
る入浴剤。 2 トコフエロール誘導体が酢酸トコフエロール
である特許請求の範囲第1項記載の入浴剤。 3 非イオン系のアルキルセルロース又はその誘
導体がメチルセルロース又はその誘導体である特
許請求の範囲第1項記載の入浴剤。[Scope of Claims] 1. A bath additive comprising tocopherol or a derivative thereof, a nonionic surfactant, and a nonionic alkyl cellulose or a derivative thereof. 2. The bath additive according to claim 1, wherein the tocopherol derivative is tocopherol acetate. 3. The bath additive according to claim 1, wherein the nonionic alkylcellulose or its derivative is methylcellulose or its derivative.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11953085A JPS61277609A (en) | 1985-06-01 | 1985-06-01 | Bathing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11953085A JPS61277609A (en) | 1985-06-01 | 1985-06-01 | Bathing agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61277609A JPS61277609A (en) | 1986-12-08 |
JPS632934B2 true JPS632934B2 (en) | 1988-01-21 |
Family
ID=14763562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11953085A Granted JPS61277609A (en) | 1985-06-01 | 1985-06-01 | Bathing agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61277609A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0374322A (en) * | 1989-08-14 | 1991-03-28 | Osamu Yoshimura | Bathing agent containing cow's milk and production thereof |
JP2003119135A (en) * | 2001-10-11 | 2003-04-23 | Ss Pharmaceut Co Ltd | Medicine for improving circulation of blood |
-
1985
- 1985-06-01 JP JP11953085A patent/JPS61277609A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS61277609A (en) | 1986-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11246390A (en) | Bath preparation having mineral spring effect particularly in the form of foaming tablet and its production and usage | |
JPH02215707A (en) | Skin cosmetic | |
JPS62111914A (en) | Novel high concentration oil content-containing anhydrous foamable composition | |
JPS63225312A (en) | Transparent or semitransparent jelly-like cosmetic | |
JPS6038310A (en) | Pearl agent composition | |
JPH0439444B2 (en) | ||
JPS63310807A (en) | Foamable cosmetic | |
JP2000229841A (en) | Mixed type bath preparation | |
CA1100043A (en) | Urea-based bath bead compositions | |
US5602178A (en) | Bath products containing menthyl lactate | |
CA1276518C (en) | Skin bleaching detergent bar | |
JPS632934B2 (en) | ||
JPS62246526A (en) | Composition for preparing local application blend before usefor drug and cosmetics | |
JP5125122B2 (en) | Adapalene-containing external preparation composition | |
JP4066466B2 (en) | Ointment containing sugar alcohols | |
JPS5827636A (en) | Oil-in-water-type emulsifier composition | |
JP2008273941A (en) | Adapalene-containing external agent composition | |
JP5338030B2 (en) | Adapalene-containing external preparation composition | |
CN1762354B (en) | Stable pharmaceutical composition containing calcium blocker | |
JP5670008B2 (en) | Adapalene-containing external preparation composition | |
JP5109382B2 (en) | Adapalene-containing external preparation composition | |
JPH0334919A (en) | Bathing agent | |
JP5109383B2 (en) | Adapalene-containing external preparation composition | |
JPS6089413A (en) | Foamable bathing agent composition | |
JP2007210928A (en) | Bath agent |